Chelerythrine

Chelerythrine is a benzophenanthridine alkaloid derived primarily from Chelidonium majus (greater celandine) and Sanguinaria canadensis. It exerts cytotoxic and antimicrobial effects largely through protein kinase C (PKC) inhibition and direct DNA intercalation, with a reported IC50 of approximately 0.7 μM in cancer cell lines.

Origin & History

Chelerythrine is a quaternary benzophenanthridine alkaloid (C₂₁H₁₈NO₄⁺) extracted from plants in the Papaveraceae family, including Chelidonium majus (greater celandine), Macleaya cordata, and Sanguinaria canadensis, as well as Rutaceae family plants like Zanthoxylum asiaticum. It exists in two pH-dependent forms: a charged iminium cation (active at acidic pH) and a neutral alkanolamine pseudo-base, typically extracted using ethanol or acid-base methods to yield chelerythrine chloride as the stable salt form.

Historical & Cultural Context

Chelerythrine-rich plants have been used for millennia across European, Chinese, and Native American traditional medicine. Chelidonium majus treated warts, jaundice, and gastrointestinal issues since Greek/Roman times, while in Traditional Chinese Medicine, Macleaya cordata and Zanthoxylum asiaticum addressed inflammation and tumors for over 1000 years.

Health Benefits

• Anticancer potential through PKC inhibition and DNA intercalation (IC50 ~0.7 μM) - Evidence: Preliminary (in vitro studies only)
• Traditional topical use for warts and skin lesions via Chelidonium majus extracts - Evidence: Traditional (no modern RCTs)
• Potential anti-inflammatory effects through NF-κB suppression - Evidence: Preliminary (preclinical models)
• Antimicrobial properties in traditional medicine applications - Evidence: Traditional (historical use in TCM)
• Possible gastrointestinal support as used historically in European herbalism - Evidence: Traditional (no clinical trials)

How It Works

Chelerythrine inhibits protein kinase C (PKC) by competing at the catalytic site, disrupting downstream phosphorylation cascades involved in cell proliferation and survival. It intercalates into double-stranded DNA, inducing strand breaks and apoptosis in rapidly dividing cells, with an IC50 near 0.7 μM in several tumor cell lines. Additionally, chelerythrine suppresses NF-κB signaling and inhibits COX-2 expression, contributing to its observed anti-inflammatory activity in preclinical models.

Scientific Research

No high-quality human clinical trials, randomized controlled trials (RCTs), or meta-analyses were identified for chelerythrine as a standalone therapeutic agent. Its evaluation is limited to preclinical in vitro and animal studies for anticancer effects, with PubMed searches yielding no human trials with PMIDs for chelerythrine monotherapy.

Clinical Summary

Evidence for chelerythrine's benefits in humans is extremely limited; virtually all mechanistic data derive from in vitro cell-line studies and rodent models with no large-scale randomized controlled trials completed to date. Animal studies have demonstrated tumor growth inhibition and antimicrobial effects against Staphylococcus aureus and Candida species, but these have not been replicated in human trials. Traditional use in European herbal medicine for topical wart and skin lesion treatment via Chelidonium majus extracts provides historical context but no quantified clinical outcomes. The overall evidence level remains preliminary, and no established therapeutic dose for humans has been validated through controlled research.

Nutritional Profile

Chelerythrine is a benzophenanthridine alkaloid (not a nutrient or food ingredient), so classical macronutrient/micronutrient profiling is not applicable. Key chemical and bioactive data: Molecular formula C21H18NO4+ (quaternary ammonium salt, typically as chloride salt C21H18ClNO4, MW ~383.83 g/mol). Primary bioactive classification: isoquinoline alkaloid. Concentration in source plant Chelidonium majus (greater celandine): aerial parts ~0.01–0.1% dry weight; latex/sap: up to 0.4–1.0% dry weight (highest concentration). Co-occurring alkaloids in same plant matrix include sanguinarine (~0.01–0.05% dry weight), berberine, coptisine, and chelidonine, which influence combined bioactivity. Bioavailability notes: Chelerythrine is a planar aromatic cation with high lipophilicity (logP ~2.8–3.2), enabling membrane penetration and DNA intercalation. Oral bioavailability in humans is poorly characterized; preclinical data suggest rapid tissue distribution but significant first-pass hepatic metabolism. It binds strongly to plasma proteins and DNA. No dietary reference intake (DRI), recommended daily allowance (RDA), or tolerable upper intake level (UL) exists, as it is a pharmacologically active alkaloid, not a dietary nutrient. Protein content: not applicable (pure alkaloid compound). Fiber/carbohydrate/fat content: not applicable. Relevant physicochemical properties affecting bioavailability: water solubility ~0.5–2 mg/mL as chloride salt; pH-dependent ionization; stability reduced under alkaline conditions and UV light exposure.

Preparation & Dosage

No clinically studied dosages exist due to absence of human trials. Preclinical studies use 1-50 μM concentrations in vitro and 5-20 mg/kg intraperitoneally in animal models. Traditional herbal preparations contain trace amounts (0.1-0.5% of dry weight) without standardization. Commercial supplements suggest 1-5 mg/day anecdotally, but this lacks clinical validation. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Sanguinarine, berberine, chelidonine, coptisine

Safety & Interactions

Chelerythrine is cytotoxic at relatively low concentrations and carries a narrow therapeutic index, making unsupervised supplementation potentially dangerous. Oral ingestion of Chelidonium majus extracts containing chelerythrine has been associated with hepatotoxicity, including cholestatic and cytolytic liver injury, and is contraindicated in individuals with pre-existing liver disease. Chelerythrine may potentiate the effects of anticoagulants and interact with CYP3A4-metabolized drugs due to enzyme inhibition observed in vitro. It is considered unsafe during pregnancy and breastfeeding given its demonstrated cytotoxic and mutagenic potential in preclinical models.